Catalog

COAG-07

Version 1.0

Acquired Coagulopathy, Consumption, and Thrombotic Patterns

A working framework for reading deteriorating platelet count, PT, aPTT, fibrinogen, and D-dimer together over time, separating an evolving consumption pattern from liver-related, dilutional, vitamin K-related, and thrombotic microangiopathy look-alikes, and deciding what needs urgent communication.

COAG-03

Version 1.0

Anticoagulants and Their Effects on Laboratory Tests

Anticoagulant drug classes act on different points in the clotting cascade, so PT, aPTT, thrombin time, and anti-Xa assays respond differently depending on which drug is present, which method is used, and which reagent is on the analyzer. Vitamin K antagonists, unfractionated and low-molecular-weight heparin, direct thrombin inhibitors, and factor Xa inhibitors map to the tests they affect, the dedicated assays used to measure them, and the specimen and reagent pitfalls that can mimic or mask an anticoagulant effect.

COAG-04

Version 1.0

Antiplatelet Drugs and Laboratory Monitoring

A working guide to matching aspirin, P2Y12 inhibitors, GP IIb/IIIa inhibitors, and phosphodiesterase III inhibitors to the platelet pathway each one alters, choosing the test family that actually answers a defined pharmacodynamic question, and recognizing the preanalytical and biological factors that can be mistaken for drug effect.

COAG-11

Version 1.0

Coagulation Cases: Putting the Entire Pattern Together

A capstone set of coagulation cases that requires the same reasoning sequence learned across prior coagulation modules: check the specimen and medication history first, build a ranked laboratory differential from the screening pattern, and choose the next test that most separates the leading explanations while preserving uncertainty.

COAG-09

Version 1.0

Distinguishing Factor Deficiency from Inhibition

After a mixing study flags a possible inhibitor, work through choosing factor assays and inhibitor studies, reading one-stage and chromogenic FVIII results together, and recognizing lupus anticoagulant, heparin, and DOAC interference before an inhibitor titer is trusted.

COAG-10

Version 1.0

Lupus Anticoagulant Evaluation as a Laboratory Workflow

Work through the screen, mix, and confirm logic that a coagulation laboratory uses to evaluate lupus anticoagulant across two complementary assay principles, dRVVT and a silica-based aPTT system, and choose a defensible report category with the correct limitation language.

COAG-08

Version 1.0

Mixing Studies Step by Step

A stepwise walk through the screening 1:1 patient-to-normal-pooled-plasma mixing study: when it is indicated, how to prepare and time it, how to read immediate versus incubated aPTT results, how to calculate a local index, and how to route the classified pattern to the right follow-up test.

COAG-05

Version 1.0

Platelet-Function Testing: Methods, Results, and Limitations

Compares light-transmission aggregometry, whole-blood impedance, high-shear closure time, lumiaggregometry, and flow cytometry as platelet-function methods, and works one PFA case through specimen validation, pattern recognition, and the boundary between a compatible pattern and a diagnosis.

COAG-01

Version 1.0

Primary Hemostasis: Vessels, Platelets, and the Initial Plug

Follow the initial platelet plug from vascular injury through aggregation, then use count, smear, and aggregometry observations to localize a quantitative, adhesion, or aggregation problem.

COAG-06

Version 1.0

Recognizing Common Bleeding-Disorder Patterns

Use platelet count, PT, aPTT, fibrinogen, and a focused bleeding history together to sort an initial bleeding differential into isolated platelet, isolated PT, isolated aPTT, combined, and normal-screen patterns, then choose a targeted next test without diagnosing from the screen alone.

COAG-02

Version 1.0

Secondary Hemostasis and the Meaning of Screening Tests

A working tour of the cell-based model of coagulation paired with what PT, aPTT, thrombin time, fibrinogen, and anti-Xa actually challenge in vitro, built around a guided case with an isolated prolonged aPTT.